CHAPTER........
AN ACT relating to health insurance; requiring certain policies of health insurance that
provide coverage for drugs approved by the Food and Drug Administration for use
in the treatment of a medical condition to include coverage for certain other uses of
those drugs; providing a penalty; and providing other matters properly relating
thereto.
THE PEOPLE OF THE STATE OF NEVADA, REPRESENTED IN
SENATE AND ASSEMBLY, DO ENACT AS FOLLOWS:
Section 1. Chapter 689A of NRS is hereby amended by adding thereto
a new section to read as follows:
1. No policy of health insurance that provides coverage for a drug
approved by the Food and Drug Administration for use in the treatment
of an illness, disease or other medical condition may be delivered or
issued for delivery in this state unless the policy includes coverage for
any other use of the drug for the treatment of cancer, if that use is:
(a) Specified in the most recent edition of or supplement to:
(1) The United States Pharmacopoeia Drug Information; or
(2) The American Hospital Formulary Service Drug Information;
or
(b) Supported by at least two articles reporting the results of scientific
studies that are published in scientific or medical journals, as defined in
21 C.F.R. § 99.3.
2. The coverage required pursuant to this section:
(a) Includes coverage for any medical services necessary to administer
the drug to the insured.
(b) Does not include coverage for any:
(1) Experimental drug used for the treatment of cancer, if that drug
has not been approved by the Food and Drug Administration; or
(2) Use of a drug that is contraindicated by the Food and Drug
Administration.
3. A policy of health insurance subject to the provisions of this
chapter that is delivered, issued for delivery or renewed on or after
October 1, 1999, has the legal effect of including the coverage required
by this section, and any provision of the policy that conflicts with the
provisions of this section is void.
NRS 689A.330 is hereby amended to read as follows:Sec. 3. Chapter 689B of NRS is hereby amended by adding thereto a
new section to read as follows:
1. No group policy of health insurance that provides coverage for a
drug approved by the Food and Drug Administration for use in the
treatment of an illness, disease or other medical condition may be
delivered or issued for delivery in this state unless the policy includes
coverage for any other use of the drug for the treatment of cancer, if that
use is:
(a) Specified in the most recent edition of or supplement to:
(1) The United States Pharmacopoeia Drug Information; or
(2) The American Hospital Formulary Service Drug Information;
or
(b) Supported by at least two articles reporting the results of scientific
studies that are published in scientific or medical journals, as defined in
21 C.F.R. § 99.3.
2. The coverage required pursuant to this section:
(a) Includes coverage for any medical services necessary to administer
the drug to the employee or member of the insured group.
(b) Does not include coverage for any:
(1) Experimental drug used for the treatment of cancer, if that drug
has not been approved by the Food and Drug Administration; or
(2) Use of a drug that is contraindicated by the Food and Drug
Administration.
3. A policy subject to the provisions of this chapter that is delivered,
issued for delivery or renewed on or after October 1, 1999, has the legal
effect of including the coverage required by this section, and any
provision of the policy that conflicts with the provisions of this section is
void.
Chapter 695B of NRS is hereby amended by adding thereto anew section to read as follows:
1. No contract for hospital or medical services that provides coverage
for a drug approved by the Food and Drug Administration for use in the
treatment of an illness, disease or other medical condition may be
delivered or issued for delivery in this state unless the contract includes
coverage for any other use of the drug for the treatment of cancer, if that
use is:
(a) Specified in the most recent edition of or supplement to:
(1) The United States Pharmacopoeia Drug Information; or
(2) The American Hospital Formulary Service Drug Information;
or
(b) Supported by at least two articles reporting the results of scientific
studies that are published in scientific or medical journals, as defined in
2. The coverage required pursuant to this section:
(a) Includes coverage for any medical services necessary to administer
the drug to a person covered under the contract.
(b) Does not include coverage for any:
(1) Experimental drug used for the treatment of cancer, if that drug
has not been approved by the Food and Drug Administration; or
(2) Use of a drug that is contraindicated by the Food and Drug
Administration.
3. A contract for hospital or medical services subject to the
provisions of this chapter that is delivered, issued for delivery or renewed
on or after October 1, 1999, has the legal effect of including the coverage
required by this section, and any provision of the contract that conflicts
with the provisions of this section is void.
Sec. 5. Chapter 695C of NRS is hereby amended by adding thereto a
new section to read as follows:
1. No evidence of coverage that provides coverage for a drug
approved by the Food and Drug Administration for use in the treatment
of an illness, disease or other medical condition may be delivered or
issued for delivery in this state unless the evidence of coverage includes
coverage for any other use of the drug for the treatment of cancer, if that
use is:
(a) Specified in the most recent edition of or supplement to:
(1) The United States Pharmacopoeia Drug Information; or
(2) The American Hospital Formulary Service Drug Information;
or
(b) Supported by at least two articles reporting the results of scientific
studies that are published in scientific or medical journals, as defined in
21 C.F.R. § 99.3.
2. The coverage required pursuant to this section:
(a) Includes coverage for any medical services necessary to administer
the drug to the enrollee.
(b) Does not include coverage for any:
(1) Experimental drug used for the treatment of cancer, if that drug
has not been approved by the Food and Drug Administration; or
(2) Use of a drug that is contraindicated by the Food and Drug
Administration.
3. Any evidence of coverage subject to the provisions of this chapter
that is delivered, issued for delivery or renewed on or after October 1,
1999, has the legal effect of including the coverage required by this
section, and any provision of the evidence of coverage that conflicts with
the provisions of this section is void.
Sec. 6.
NRS 695C.330 is hereby amended to read as follows:(c) The health care plan does not furnish comprehensive health care
services as provided for in NRS 695C.060;
Sec. 7. The amendatory provisions of this act do not apply to offenses
that are committed before October 1, 1999.
~